Pseudomonas Aeruginosa Infections in Cancer Patients

  • Kenneth V.I. Rolston
Part of the Perspectives on Critical Care Infectious Diseases book series (CCID, volume 7)

Abstract

Cancer patients, particularly those with neutropenia, are at increased risk of developing bacterial infections (1). In the four decades since the association between neutropenia and infection was recognized, the epidemiology of bacterial infection in cancer patients has undergone several changes, with gram-positive organisms and gram-negative bacilli being the predominant pathogens at different stages. Many of these epidemiologic shifts have been influenced by changes in the nature and intensity of chemotherapeutic and immunosuppressive regimens, prophylactic and empiric antimicrobial regimens, and the increased usage of vascular access catheters and prosthetic devices (2,3).Pseudomonas aeruginosa emerged as a common cause of gram-negative infection in cancer patients during the 1960’s and, before the availability of agents such as carbenicillin, was associated with mortality rates in excess of 90% (4). Since then, the availability of potent anti-pseudomonal agents and significant improvements in supportive care have reduced the mortality to approximately 25–30% (5,6). Substantial regional and institutional variations in the frequency of infections caused by P. aeruginosa have been documented (7,8). The treatment of P. aeruginosa infections continues to foster much discussion and debate among various experts, some of whom advocate the use of synergistic, bactericidal combinations for the treatment of all pseudomonal infection in neutropenic patients, whereas others do not. These issues will be discussed in this chapter, with an emphasis on current trends in North America.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Bodey GP. Infection in cancer patients: a continuing association. Am J Med 1986; 81(Suppl IA):11–26.PubMedCrossRefGoogle Scholar
  2. 2.
    Koll BS, Brown AE. The changing epidemiology of infections at cancer hospitals. Clin Infect Dis 1993; 17(Suppl. 2):S322–28.PubMedCrossRefGoogle Scholar
  3. 3.
    Zinner SH. Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 1999; 29:490–94.PubMedCrossRefGoogle Scholar
  4. 4.
    Hersh EM, Bodey GP, Nies BA, Freireich EJ. Causes of death in acute leukemia: a ten year study of 414 patients from 1954–1963. JAMA 1965; 193:105–109.PubMedCrossRefGoogle Scholar
  5. 5.
    Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia: Retrospective analysis of 410 episodes. Arch Intern Med 1985; 145:1621–29.PubMedCrossRefGoogle Scholar
  6. 6.
    Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KVI, Tarrand JJ, Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer. Retrospective analysis of 245 episodes. Arch Intern Med 2000; 160:501–09.PubMedCrossRefGoogle Scholar
  7. 7.
    Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 1993; 328:1323–32.PubMedCrossRefGoogle Scholar
  8. 8.
    Rolston KVI, Tarrand JJ. Pseudomonas aeruginosa - Still a frequent pathogen in patients with cancer: 11-year experience from a comprehensive cancer center. Clin Infect Dis 1999; 29:463–64.PubMedCrossRefGoogle Scholar
  9. 9.
    Elting LS, Bodey GP, Fainstein V. Polymicrobial septicemia in the cancer patient. Medicine 1986; 65:218–25.PubMedCrossRefGoogle Scholar
  10. 10.
    Rolston, KVI, Bodey, GP. “Infections in patients with cancer”. In Cancer Medicine, e5 JF Holland and E Frei, eds, Hamilton, Ontario, BC Decker, 2000.Google Scholar
  11. 11.
    Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KVI, Shenep JL, Young LS. 2002 Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34:730–51.PubMedCrossRefGoogle Scholar
  12. 12.
    Rolston KVI. New trends in patient management: Risk-based therapy for febrile patients with neutropenia. Clin Infect Dis 1999; 29:515–21.PubMedCrossRefGoogle Scholar
  13. 13.
    Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 1975; 135:715–19.PubMedCrossRefGoogle Scholar
  14. 14.
    Rolston, KVI. “Infections in patients with solid tumors”. In Textbook of Febrile Neutropenia.“ KVI Rolston and EB Rubenstein, eds, United Kingdom, Martin Dunitz, 2001.Google Scholar
  15. 15.
    Rolston KVI, Dholakia N, Rodriguez S, Rubenstein EB. Nature and outcome of febrile episodes in patients with pancreatic and hepatobiliary cancer. Support Care Cancer 1995; 3:414–17.PubMedCrossRefGoogle Scholar
  16. 16.
    Afif C, Raad I. “Evaluation and management of vascular assess device infections in febrile neutropenic cancer patients”. In Textbook of Febrile Neutropenia, KVI Rolston and EB Rubenstein, eds United Kingdom, Martin Dunitz, 2001.Google Scholar
  17. 17.
    Bodey GP. Synergy: Should it determine antibiotic selection in neutropenic patients (Editorial). Arch Intern Med 1985; 145:1964–66.PubMedCrossRefGoogle Scholar
  18. 18.
    Korvick JA, Yu VL. Antimicrobial agent therapy for Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991; 35:2167–72.PubMedCrossRefGoogle Scholar
  19. 19.
    Pizzo PA, Hathorn JW, Hiemenez J, et al. A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 1986; 315:552–58.PubMedCrossRefGoogle Scholar
  20. 20.
    Wade JF, Johnson DE, Bustamante CI. Monotherapy for empiric treatment of fever in granulocytopenic cancer patients. Am J Med 1986; 80:85–95.PubMedGoogle Scholar
  21. 21.
    Liang R, Yung R, Chiu E, et al. Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients. Antimicrob Agents Chemother 1990; 34:1336–41.PubMedCrossRefGoogle Scholar
  22. 22.
    De Pauw BE, Deresinski SC, Feld R, Lane-Allman EF, Donnelly JP. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer: a multicenter randomized trial: The Intercontinental Antimicrobial Study Group. Ann Intern Med 1994; 120:834–44.PubMedGoogle Scholar
  23. 23.
    Piccart M, Klastersky J, Meunier F, Lagast H, Van Laethem Y, Werrts D. Single-drug versus combination empirical therapy for gram-negative bacilliary infections in febrile cancer patients with and without granulocytopenia. Antimicrob Agents Chemother 1984; 26:870–75.PubMedCrossRefGoogle Scholar
  24. 24.
    Hill M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87:540–46.CrossRefGoogle Scholar
  25. 25.
    De Jongh CA, Joshi JH, Newman KA, et al. Antibiotic synergism and response in gram-negative bacteremia in granulocytopenic cancer patients. Am J Med 1986; 80:96–100.PubMedCrossRefGoogle Scholar
  26. 26.
    Rolston K, Berkey P, Bodey GP, Anaissie E, Khardori N, Joshi J, Keating M, Holmes F, Cabanillas F, Elting L. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 1992; 152:283–91.PubMedCrossRefGoogle Scholar
  27. 27.
    Bodey GP. Antibiotics in patients with neutropenia. Arch Intern Med 1984; 144:1845–51.PubMedCrossRefGoogle Scholar
  28. 28.
    Meunier F, Zinner SH, Gaya H, et al. Prospective randomized evaluation of ciprofloxacin versus piperacillin plus amikacin for empiric antibiotic therapy of febrile granulocytopenic cancer patients with lymphomas and solid tumor. European Organization for Research on Treatment of Cancer International Antimicrobial Therapy Cooperative Group. Antimicrob Agents Chemother 1991; 35:873–78.PubMedCrossRefGoogle Scholar
  29. 29.
    Winston DJ, Lazarus HM, Beveridge RA, et al. Randomized, double-blind multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients. Clin Infect Dis 2001; 32:381–90.PubMedCrossRefGoogle Scholar
  30. 30.
    Freifeld A, Pizzo P. Use of fluoroquinolones for empirical management of febrile neutropenia in pediatric cancer patients. Pediatr Infect Dis J 1997; 16:140–46.PubMedCrossRefGoogle Scholar
  31. 31.
    Bodey GP, Ho DH, Elting L. Survey of antibiotic susceptibility among gram-negative bacilli at a cancer hospital. Am J Med 1988; 85(Suppl 1A):49–51.PubMedCrossRefGoogle Scholar
  32. 32.
    Rolston KVI, Elgin., Waguespack S, Ho DH, LeBlanc B, Bodey GP. Survey of antibiotic susceptibility among gram-negative bacilli at a cancer center. Chemotherapy 1996; 42:348–53.PubMedCrossRefGoogle Scholar
  33. 33.
    Jacobson K, Rolston K, Elting L, LeBlanc B, Whimbey E, Ho DH. Susceptibility surveillance among gram-negative bacilli at a cancer center. Chemotherapy 1999; 45:325–34PubMedCrossRefGoogle Scholar
  34. 34.
    Ozer H, ASCO Ad Hoc Colony-Stimulating Factor Guidelines Expert Panel: American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines. J Clin Oncol 1984; 12:2471–2508.Google Scholar
  35. 35.
    ASCO Ad Hoc Colony-Stimulating Factor Guidelines Expert Panel. Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines. J Clin Oncol 1996; 14:1957–60.Google Scholar
  36. 36.
    litibel K, Dale D, Engert A, Liles WC. Current status of granulocyte (neutrophil) transfusion therapy for infectious diseases. Clin Infect Dis 2001; 183:321–28.Google Scholar
  37. 37.
    Rolston KVI. Prediction of neutropenia. International J Antimicrob Agents 2000; 16:11315.Google Scholar
  38. 38.
    Elting LS, Rubenstein EB, Rolston KVI, Bodey GP. Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 1997; 25:247–59.PubMedCrossRefGoogle Scholar
  39. 39.
    Bernard GR, Vincent JL, Laterre PR, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699–709.PubMedCrossRefGoogle Scholar
  40. 40.
    National Comprehensive Cancer Network (NCCN). Leukopenic Sepsis Guidelines Panel Members, NCCN Practice Guidelines for Fever and Neutropenia. NCCN Proceedings, Oncology 1999; 13:197–257.Google Scholar
  41. 41.
    Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with fluoroquinolones in neutropennic patients: a meta-analysis. Clin Infect Dis 1996; 23:795–805.PubMedCrossRefGoogle Scholar
  42. 42.
    Rolston KVI. Commentary: Chemoprophylaxis and bacterial resistance in neutropenic patients. Infect Dis Clin Pract 1998; 7:202–204.CrossRefGoogle Scholar
  43. 43.
    Jones RN. Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia. Clin Infect Dis 1999; 29:495–502.PubMedCrossRefGoogle Scholar
  44. 44.
    National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. Document M7-A-5. Wayne, PA: National Committee for Clinical Laboratory Standards, 2000.Google Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Kenneth V.I. Rolston
    • 1
  1. 1.M. D. Anderson Cancer CenterThe University of TexasHoustonUSA

Personalised recommendations